Fenbufen, a new non-steroidal anti-inflammatory agent in rheumatoid arthritis, its efficacy and toxicity.
Fenbufen, a new butanoic acid derivative with anti-inflammatory properties, was evaluated in an open-label study. It was found that fenbufen was an effective anti-inflammatory agent with tolerable and acceptable potential side-effects. Its advantages appeared to be its long clinical half-life and relatively mild toxicity and/or allergic response.
D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001713:Biphenyl Compounds / Q000008:administration & dosage / Q000627:therapeutic use / Q000633:toxicity; D002986:Clinical Trials as Topic; D006801:Humans; D008875:Middle Aged; D010654:Phenylbutyrates; D011422:Propionates / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity
D000893:Anti-Inflammatory Agents; D001713:Biphenyl Compounds; D010654:Phenylbutyrates; D011422:Propionates; C010725:fenbufen